A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazolebased triple therapy for the eradication of Helicobacter pylori in dyspeptic patients-Reference-Cited by-同舟云学术

A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazolebased triple therapy for the eradication of Helicobacter pylori in dyspeptic patients

Published:2013-08-01 Issue:4 Volume:24 Page:316-321
ISSN:1300-4948
Container-title:The Turkish Journal of Gastroenterology
language:
Short-container-title:Turk J Gastroenterol

Author:

AVSAR Erol,TIFTIKCI Arzu,POTUROGLU Sule,ERZIN Yusuf,KOCAKAYA Ozan,DINCER Dinc,YILDIRIM Bulut,GULITER Sefa,TURKAY Cansel,YILMAZ Ugur,ONUK Mehmet Derya,BOLUKBASI Cengiz,ELLIDOKUZ Ender,BEKTAS Ahmet,TASAN Guralp,AYTUG Necip,ATES Yuksel,KAYMAKOGLU Sabahattin

Publisher

AVES Publishing Co.

Subject

Gastroenterology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bismuth-containing Standard Triple Therapy the First-line Eradication Therapy for Helicobacter pylori;The Korean Journal of Helicobacter and Upper Gastrointestinal Research;2021-12-10

2. Efficacy of bismuth added to standard triple therapy as the first‐line eradication regimen for Helicobacter pylori infection;Helicobacter;2021-03

3. The Efficacy of Bismuth-based Quadruple and Sequential Therapies in Helicobacter pylori Eradication;Meandros Medical and Dental Journal;2020-08-20

4. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies;The Turkish Journal of Gastroenterology;2019-05-03

5. Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta‐analysis;Helicobacter;2019-01-30